Loading
Photodynamic Therapy / Photochemotherapy / Phototherapy · Journal article
Medical Gas Research · March 11, 2026
Raises a question worth testing. It does not answer one.
This review examines the concept of conjugating indomethacin, a COX-2 inhibitor, with photosensitizers to enhance photodynamic therapy efficacy in COX-2-overexpressing tumors. The approach aims to reduce PDT-induced protumorigenic inflammation while improving tumor accumulation of photosensitizers, though no primary efficacy or safety data are reported.
Journal article. Cancer patients with COX-2-overexpressing tumors.
Cyclooxygenase-2 overexpression and prostaglandin E2 secretion limit PDT efficacy in many tumors Combining indomethacin COX-2 inhibitor with photosensitizer reduces inflammation and enhances PDT treatment IMC-conjugated photosensitizers show promising targeted, improved tumor accumulation, and effective cancer phototherapy
No quantitative efficacy, safety, or pharmacokinetic outcomes provided
Indomethacin-conjugated photosensitizers represent a potential strategy to overcome PDT-induced inflammation that limits therapeutic efficacy, particularly in tumors with COX-2 overexpression. The approach remains investigational without reported clinical outcomes or quantified benefits.
Review discussing a therapeutic strategy combining indomethacin with photosensitizers to enhance photodynamic therapy by targeting COX-2, without presenting primary clinical or experimental data.
As stated by the source record.
Indomethacin-conjugated photosensitizers represent a potential strategy to overcome PDT-induced inflammation that limits therapeutic efficacy, particularly in tumors with COX-2 overexpression. The approach remains investigational without reported clinical outcomes or quantified benefits.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
FactsPhotodynamic therapy (PDT) kills cancer cells via the generation of reactive oxygen species but can also trigger harmful protumorigenic effects.Cyclooxygenase-2 (COX-2) overexpression and prostaglandin E2 secretion limit PDT efficacy in many tumors.Combining indomethacin (IMC) COX-2 inhibitor with photosensitizer reduces inflammation and enhances PDT treatment.IMC-conjugated photosensitizers show promising targeted, improved tumor accumulation, and effective cancer phototherapy.Open QuestionsHow can PDT-induced protumorigenic inflammation be effectively minimized?Can IMC conjugation with photosensitizers inhibit inflammation and improve the accumulation of photosensitizers in cancer cells?What design strategies best optimize IMC-conjugated photosensitizers? Photodynamic therapy is a non-invasive treatment that directly kill cancer cells through the generation of reactive oxygen species. However, photodynamic therapy can also paradoxically trigger harmful protumorigenic effects, such as overexpression cyclooxygenase-2 and secretion of prostaglandin E2 in various type of tumors, limiting the overall therapeutic efficacy of photodynamic therapy. The inhibition of prostaglandin E2 secretion using nonselective cyclooxygenase inhibitors such as indomethacin, a widely used anti-inflammatory drug, with photodynamic therapy offers a promising approach for reducing light-induced inflammation and enhancing the effectiveness of photodynamic therapy. In addition, indomethacin and other cyclooxygenase-2 inhibitors have been conjugated with other therapeutic agents to develop tumor-targeted drug delivery systems. Their ability to selectively target and accumulate in cancer cells makes them attractive for delivering a wide range of photosensitizers directly to diseased tissues. Given the considerable progress in this area, this review outlines the photodynamic therapy application of various indomethacin-conjugated photosensitizers for the treatment of cyclooxygenase-2 overexpressed tumor cells, aiming to improve light-mediated effectiveness and reduce off-target effects. Finally, we highlight and discuss future perspectives and challenges in the development of indomethacin-conjugated photodynamic therapy agents.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.